Molecular markers of prostate cancer outcome

Eur J Cancer. 2005 Apr;41(6):858-87. doi: 10.1016/j.ejca.2004.12.035.


Molecular markers have the potential to serve not only as prognostic factors but may be targets for new therapeutic strategies and predictors of response in a range of cancers. Prostate cancer development and progression is predicated on a series of genetic and epigenetic events within the prostate cell and its milieu. Within this review, we identify candidate molecules involved in diverse processes such as cell proliferation, death and apoptosis, signal transduction, androgen receptor (AR) signalling, cellular adhesion and angiogenesis that are linked to outcome in prostate cancer. Current markers with potential prognostic value include p53, Bcl-2, p16INK4A, p27Kip1, c-Myc, AR, E-cadherin and vascular endothelial growth factor. Evolving technology permits the identification of an increasing number of molecular markers with prognosis and predictive potential. We also review the use of gene microarray analysis in gene discovery as a means of identifying and cosegregating novel markers of prostate cancer outcome. By integrating selected markers into prospective clinical trials, there is potential for us to provide specific targeted therapy tailored for an increasing number of patients.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Apoptosis / physiology
  • Biomarkers, Tumor / analysis*
  • Cell Adhesion / physiology
  • Cell Communication / physiology
  • Cell Cycle / genetics
  • Cell Death / genetics
  • Cell Death / physiology
  • Cell Proliferation
  • Genetic Markers / physiology*
  • Humans
  • Male
  • Neovascularization, Pathologic / pathology
  • Prognosis
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / pathology
  • Receptors, Androgen / physiology
  • Signal Transduction / physiology


  • Biomarkers, Tumor
  • Genetic Markers
  • Receptors, Androgen